期刊文献+

重症儿童IgA肾病采用来氟米特与环磷酰胺治疗的临床效果分析 被引量:3

Critically ill children from the IgA nephropathy,and clinical effect of cyclophosphamide analysis
下载PDF
导出
摘要 目的:观察重症儿童IgA肾病采用来氟米特与环磷酰胺治疗效果。方法:盲选我院收治的76例重症儿童IgA肾病患者,均分为两组,对照组采用环磷酰胺治疗,观察组采用来氟米特联合激素治疗,比较两组临床治疗效果。结果:两组缓解率、不良反应情况均有明显差异;比较治疗前治疗后的尿蛋白定量、总蛋白以及血清白蛋白有明显差异,观察组改善情况明显优于对照组,P<0.05,差异有统计学意义。观察组甘油三酯、血清胆固醇与治疗前相比差异显著,有统计学意义(P<0.05)。对照组则无明显差异。结论:采用来氟米特与环磷酰胺治疗重症儿童IgA肾病,可有效改善患者的血脂水平,提高生命质量,应用效果显著,值得推广。 objective: to analyze the severe children from using IgA nephropathy with cyclophosphamide therapy effect. Methods: blind to ehoose our hospital 76 cases of critically ill children, IgA nephropathy patients were divided into two groups, control group treated with cyclophosphamide, observation group from the combined hormone therapy, compared two groups of patients with the clinical therapeutic effect. Results: the remission rate, adverse reaction of two groups of patients have obvious difference; Compared before treatment after treatment of urine protein quantitative serum albumin, total protein, and have obvious differences, and improve observation group was better than control group, P〈0.05 c.ompared with difference was statistically significant. Observation group triglyceride and serum cholesterol in patients with significant difference was statistically significant compared with before treatment (P〈0.05). The control group, no significant differences. Conclusion: using to fluorine mih and cyclophosphamide treatment of severe children IgA nephropathy, which can effectively improve the patient's blood lipid levels, improve the quality of life in children with, application effect is remarkable, is worth promoting.
作者 崔卫国
出处 《北方药学》 2014年第7期87-88,共2页 Journal of North Pharmacy
关键词 重症儿童 IGA肾病 来氟米特 环磷酰胺 intensive IgA nephropathy in children From mih cyclophosphamide
  • 相关文献

参考文献4

二级参考文献22

  • 1叶琨,刘映红,刘伏友,彭佑铭.原发性IgA肾病106例临床与病理分析[J].中华肾脏病杂志,2006,22(5):295-296. 被引量:32
  • 2陈迎章,黄建中.IgA肾病的研究现状[J].海南医学院学报,1996,2(3):135-138. 被引量:1
  • 3Kalafunhi R,Kiyoshi Y,Oh Y,et al.Glomerular scoreas a prognosticator in igA nephropat hy:it s usefulnees and limitation[J].ClinNephrol,1998,49(1):128.
  • 4Alexopoulos E.Treatment of primary IgA nephropathy[J].Kidney Int,2002:65:341-355.
  • 5Mera J,Unhida S,Naga.se M.Clinicopat hologic study onprognostic markers in IgA nephropat hy[J].Nephron,2000,84(1):148-157.
  • 6Cherwinski IIM,Cohn RG,Cheung P,et al.The immunosupp ressant leflunnmide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis[J].J Pharmacol Exp Ther,1995,275:1043-1049.
  • 7Pozzi C, Andml]i S, Pani A, et al. Addition of azathioprine to corficoste- voids does not benefit patients with IgA nephropathy [ J ] Am Sot: Nephrology,2010,21 (10) : 1783 - 1790.
  • 8Haas M. Histologic subclaification of lgA nephropathy: a clinicepatho- logic study of 244 cases. [J]. Am J Kidney Dis,1997,29 (6) :829 - 842.
  • 9Mestccky J, Tomana M, Crowley-Nowick PA, et al. Defective galactosyla- fion and clearance of IgA1 molecules as a possible efiopathogenic factor in IgA nephropathy. [ J ]. C ontrib Nephrol, 1993,104 ( 1 ) : 172 - 182.
  • 10张月兰,田歌,齐国先.氯沙坦联合碳酸氢钠降低冠心病患者血尿酸水平的疗效观察[J].山西医药杂志(上半月),2009,38(3):253-255. 被引量:2

共引文献23

同被引文献36

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部